Search results

Order by most recent / most popular / relevance

Results: 1-10 of 55

New York Court considering equitable claim for medical monitoring

Alston & Bird LLP
-
USA
-
May 7 2013

The New York Court of Appeals may soon have to decide whether an independent equitable claim for medical monitoring is a recognized claim in New York

Council for Responsible Nutrition releases recommended guidelines for caffeine-containing dietary supplements

Alston & Bird LLP
-
USA
-
April 5 2013

On April 3, 2013, the Council for Responsible Nutrition ("CRN") proposed voluntary guidelines for the labeling of dietary supplements containing

Dietary supplement manufacturer “likes” post on Facebook; FDA does not

Alston & Bird LLP
-
USA
-
March 5 2013

On February 26, 2013, the U.S. Food & Drug Administration (FDA) published a Warning Letter issued to a dietary supplement manufacturer because, among

Medical device developments

Alston & Bird LLP
-
USA
-
March 4 2013

On February 25, 2013, the U.S. Food and Drug Administration (FDA) issued a proposed rule amending its regulations to update the standards for FDA

Brand-name drug manufacturers to Alabama Supreme Court: “if ever a case demanded oral argument, this one does.”

Alston & Bird LLP
-
USA
-
February 21 2013

We recently wrote about the Alabama Supreme Court decision holding that a consumer can bring a failure-to-warn claim against the brand-name drug

FDA will not challenge Second Circuit off-label promotion decision

Alston & Bird LLP
-
USA
-
February 1 2013

The U.S. Food and Drug Administration (FDA) has issued a statement stating that it will not seek review of a Second Circuit decision, which held that

The Ninth Circuit Court of Appeals holds that Arizona state law failure-to-warn product liability claims involving a medical device was not pre-empted by the Medical Control Device Amendments to the Food, Drug, and Cosmetic Act

Alston & Bird LLP
-
USA
-
January 23 2013

On January 10, 2013, the Ninth Circuit Court of Appeals held that amendments to a federal statute did not preempt Arizona state law failure-to-warn

Alabama Supreme Court: brand-name drug manufacturers can be liable for patient’s injuries caused by generic drug

Alston & Bird LLP
-
USA
-
January 14 2013

A few months ago, Congress introduced the Patient Safety and Generic Labeling Improvement Act (S.2295, 112th Cong. (2d Sess. 2012)), promulgated in

FDA proposes highly anticipated food safety regulations

Alston & Bird LLP
-
USA
-
January 11 2013

In an effort to combat the steady rise of foodborne illnesses, on Friday, January 4, 2013, the U.S. Food and Drug Administration (FDA) proposed the

EPA and CPSC collaborate on nanomaterials

Alston & Bird LLP
-
USA
-
December 13 2012

The U.S. Environmental Protection Agency (EPA) and the U.S. Consumer Product Safety Commission (CPSC) have agreed to a collaborative effort for worldwide research to determine any potential impacts nanomaterials have on health and the environment

next >